Recent additions to our Life Sciences Notes blog include our contribution to this year’s Legal 500 ‘Life Sciences Yearbook: Design for Life’. With major developments continuing to affect the UK regulatory and investment landscape, this article dissects the latest trends shaping the industry, both in the UK and abroad, taking in clinical trial reforms, EU regulatory changes, M&A and investment activity, Merger control and FDI developments. Other updates include a review of the European Commission’s report on competition enforcement in the pharmaceuticals sector, as well as an analysis of the role of the Unitary Patent Court’s (UPC) central division seat in Milan.

Featured articles can be accessed via the links below.

  1. The year the United Kingdom becomes a globally leading life sciences hub?
  2. European Commission’s report on competition enforcement in the pharmaceuticals sector
  3. With the Headquarters Agreement for the Milan seat concluded, we look at the role of the UPC central division
  4. Competition Law and Biosimilars: Time for a New Approach or Not Yet?
  5. Cyber Security: Pharmaceutical Companies on High Alert
  6. Another Chapter in the ‘Pay for Delay Saga’: The Teva-Cephalon Settlement Agreement